PubMed ID:
11386927
Public Release Type:
Journal
Publication Year: 2001
Affiliation: Case Western Reserve University, Clinical Hypertension Program, University Hospitals of Cleveland and the Louis Stokes Cleveland Veterans Affairs Medical Center, 10900 Euclid Ave, Wood Bldg Room W-165, Cleveland, OH 44106-4982, USA. jxw20@po.cwru.edu
DOI:
https://doi.org/10.1001/jama.285.21.2719
Authors:
Greene T,
Lash J,
Toto RD,
Lewis JB,
African American Study of Kidney Disease and Hypertension (AASK) Study Group,
Agodoa LY,
Appel L,
Bakris GL,
Beck G,
Bourgoignie J,
Briggs JP,
Charleston J,
Cheek D,
Cleveland W,
Douglas JG,
Douglas M,
Dowie D,
Faulkner M,
Gabriel A,
Gassman J,
Hall Y,
Hebert L,
Hiremath L,
Jamerson K,
Johnson CJ,
Kopple J,
Kusek J,
Lea J,
Lipkowitz M,
Massry S,
Middleton J,
Miller ER 3rd,
Norris K,
O'Connor D,
Ojo A,
Phillips RA,
Pogue V,
Rahman M,
Randall OS,
Rostand S,
Schulman G,
Smith W,
Thornley-Brown D,
Tisher CC,
Wright JT Jr,
Xu S
Incidence of end-stage renal disease due to hypertension has increased in recent decades, but the optimal strategy for treatment of hypertension to prevent renal failure is unknown, especially among African Americans.